22 July 2025 in Cancer Research Communications
Immunotherapy has revolutionized the treatment paradigms of several cancer types, yet only a subset of patients derived durable clinical benefit. Ferroptosis is a programmed cell death facilitated by iron-driven overload of lipid peroxidation. We aimed to evaluate ferroptosis activity based on tumor transcriptomic profiles to determine its predictive value for immunotherapy outcomes. We analyzed RNA-sequencing data from eight independent cohorts of patients with urothelial, gastric, skin and lung cancers treated with immune checkpoint inhibitors or adoptive T cell therapy. A ferroptosis activity model was constructed using downstream gene expression signatures. Associations with overall survival (OS) and progression-free survival (PFS) were assessed. Potential mechanisms were explored by examining immunosenescence, interferon-γ immune response pathway and immunogenic cell death. Ferroptosis-high tumors were associated with significantly improved OS and PFS across multiple cancer types. Integrating ferroptosis scores with tumor mutation burden (TMB), liver metastasis status, and immune microenvironment phenotypes (inflamed, excluded, desert) enhanced patient stratification and predictive accuracy. Mechanistically, ferroptosis enhanced immune response by promoting immunogenic cell death and attenuating immunosenescence. In conclusion, elevated ferroptosis activity correlates with improved immunotherapy outcomes, potentially through increased tumor immunogenicity and reduced immunosenescence. Ferroptosis-based biomarkers may aid in identifying patients more likely to benefit from immunotherapy.
17 June 2026 in Cancer Research
Pancreatic cancer remains one of the deadliest malignancies, with gemcitabine-based chemotherapy as the mainstay treatment for most patients, yet resistance emerges almost universally. A defining feature of pancreatic cancer is its dense, fibroblast-rich stroma, in which heterogeneous cancer-associated fibroblasts (CAF) actively shape tumor biology and therapeutic response. Here, we elucidated a stromal–metabolic mechanism through which chemoresistant CAFs confer gemcitabine resistance. We identified a subset of mitophagy-competent CAFs that enhanced pancreatic cancer gemcitabine resistance. The epithelial–mesenchymal transition transcription factor ZEB1 acts as a master regulator of this CAF-driven chemoresistance program, being upregulated and epigenetically activated via SETD1A-mediated H3K4 methylation in gemcitabine-resistant CAFs. ZEB1 promotes BNIP3-mediated mitophagy in CAFs, leading to increased nucleotides secretion, which competitively inhibited gemcitabine incorporation into cancer cells while simultaneously supplying pyrimidine metabolism substrates for pyrimidine metabolism. Concurrently, ZEB1 transcriptionally activated CXCL8, engaging the CXCR1/2–MEK/ERK pathway in tumor cells and further augmenting pyrimidine metabolism via the RRM1/E2F1/G6PD axis, collectively diminishing gemcitabine cytotoxicity. Notably, combined inhibition of CXCR1/2 or G6PD with gemcitabine robustly suppressed tumor growth and restored chemosensitivity both in vitro and in vivo. These findings uncover a key stromal–metabolic axis in pancreatic cancer, linking mitophagy CAF activity to metabolic remodeling in tumor cells and identifying ZEB1 and its downstream network as actionable targets to overcome chemoresistance. Significance: This study reveals that ZEB1 reprograms mitophagy-competent CAFs to promote gemcitabine resistance by enhancing nucleotide supply and activating tumor pyrimidine metabolism, supporting therapeutic targeting of the ZEB1–CXCL8–pyrimidine axis in pancreatic cancer.
4 March 2025 in Clinical Cancer Research
Summary: The shared HLA-bound neoepitopes in pancreatic ductal adenocarcinoma (PDAC) represent a novel class of noncanonical antigens with single amino acid substitutions resulting from translational errors. These peptides, shared across patients with PDAC, showed higher immunogenicity than wild-type counterparts, offering potential candidates for specific immunotherapy development in PDAC. See related article by Zhang et al., p. 1956